SEC Form 4 · accession 0001652252-17-000004
BIO-RAD LABORATORIES, INC. · BIO BIO.B
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John Goetz
Officer — EVP, Chief Operating Officer
Period of report
Mar 2, 2017
Accepted (ET)
Mar 2, 2017 · 7:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000012208
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Bio-Rad A Common StockF1 | Mar 2, 2017 | M | 3,500 | $75.32 | A | 61,422 | D | |
| Bio-Rad A Common StockF2 | Mar 2, 2017 | S | 3,500 | $196.3396 | D | 57,922 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F3 | $75.32 | Mar 2, 2017 | M | 3,500 | D | — | Aug 1, 2017 | Bio-Rad A Common Stock | 3,500 | 0 | D |
Explanation of responses
- F1Includes 4.6707 shares acquired under the Bio-Rad Employee Stock Purchase Plan on 12/31/2016.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $196.306 to $196.415 inclusive. The reporting person undertakes to provide to Bio-Rad Laboratories, Inc., any security holder of Bio-Rad Laboratories, Inc., or the staff of the Securites and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- F3The option vested in five equal annual installments beginning on August 1, 2008.